Clovis Oncology, Inc.
CLVSQ
OTC PK
| 09/30/2022 | 06/30/2022 | 03/31/2022 | 12/31/2021 | 09/30/2021 | |
|---|---|---|---|---|---|
| Net Income | -56.02M | -71.33M | -60.17M | -64.39M | -67.41M |
| Total Depreciation and Amortization | 1.89M | 1.90M | 1.92M | 2.00M | 2.02M |
| Total Amortization of Deferred Charges | 566.00K | 561.00K | 558.00K | 554.00K | 616.00K |
| Total Other Non-Cash Items | 6.76M | 15.50M | 7.00M | 7.57M | 6.39M |
| Change in Net Operating Assets | 6.20M | 18.24M | -7.81M | 12.93M | 12.31M |
| Cash from Operations | -40.61M | -35.13M | -58.50M | -41.34M | -46.07M |
| Capital Expenditure | -89.00K | -46.00K | -62.00K | -69.00K | -89.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -89.00K | -46.00K | -62.00K | -69.00K | -89.00K |
| Total Debt Issued | 6.18M | 8.76M | 9.22M | 9.73M | 10.58M |
| Total Debt Repaid | -- | -- | -- | 0.00 | -64.42M |
| Issuance of Common Stock | 0.00 | 384.00K | 28.64M | 3.44M | 41.52M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | 0.00 | 0.00 |
| Cash from Financing | 6.18M | 9.14M | 37.86M | 13.17M | -12.33M |
| Foreign Exchange rate Adjustments | -1.74M | -1.63M | -487.00K | -276.00K | 229.00K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -36.26M | -27.66M | -21.19M | -28.52M | -58.26M |
